IRLAB announces that equity research company Edison initiates coverage of the company

June 2, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that equity research company Edison Investment Research has been engaged by IRLAB to produce regular, in-depth research on the company. The intention is to raise the visibility of the company and enable investors and stakeholders to develop an improved understanding of the business.

Read More >

IRLAB’s drug candidate mesdopetam’s Phase I results published in scientific journal PR&P

May 25, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a scientific paper reporting the clinical phase I study results for drug candidate mesdopetam has been published in the journal Pharmacology Research & Perspectives (PR&P). Mesdopetam is a dopamine D3 receptor antagonist and is currently being evaluated in an international Phase IIb/III study for the treatment of levodopa-induced dyskinesias (LIDs) in Parkinson’s disease.

Read More >

Report from the annual general meeting of IRLAB Therapeutics AB

May 6, 2021 Regulatory

IRLAB Therapeutics AB held its Annual General Meeting on May 6, 2021. In order to counteract the virus that causes covid-19, the Annual General Meeting was held solely by postal voting without physical participation. The following main resolutions were resolved upon at the Annual General Meeting. Disposition of the company´s results The AGM resolved that […]

Read More >


IR contact

Viktor Siewertz, CFO
+46(0)72 710 70 70